Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers.
Simona Pichini, Mitona Pujadas, Emilia Marchei, Manuela Pellegrini, Jimena Fiz, Roberta Pacifici, Piergiorgio Zuccaro, Magí Farré, Rafael De la Torre
Journal of pharmaceutical and biomedical analysis June 9, 2008 DOI: 10.1016/j.jpba.2007.12.039 via PubMed
Summary
AI-generated from the abstractA liquid chromatography-mass spectrometry (LC-MS) method was developed to measure ten designer drugs—including MDMA, several 2C-series phenethylamines, m-CPP, and tryptamines—in urine samples from 32 consumers. Solid-phase extraction at pH 6 was applied to both non-hydrolyzed and enzymatically hydrolyzed urine, with 3,4-methylendioxypropylamphetamine (MDPA) as an internal standard. Chromatographic separation used a C18 column with a gradient of ammonium bicarbonate and acetonitrile, and detection was performed in single ion monitoring mode with electrospray ionization. Limits of quantification ranged from 20 to 60 ng/mL, calibration curves were linear to 2000 ng/mL, and mean recoveries were 55.4–95.6%. Higher analyte concentrations in hydrolyzed samples indicated the presence of conjugated compounds.
Study at a glance
| Characteristics | Method development and validation Peer reviewed |
|---|---|
| Sample size | 32 |
| Population | Consumers of the investigated designer drugs |
| Keywords | Drug detection Forensic toxicology Lc-ms Designer drugs Drug metabolism |
| Citations | 59 |
| Key finding | The LC-MS method successfully quantified ten designer drugs and their conjugated metabolites in human urine with limits of quantification between 20 and 60 ng/mL and linearity up to 2000 ng/mL. |
Abstract
A procedure based on liquid chromatography-mass spectrometry (LC-MS) is described for determination of 3,4-methylenedioxymethamphetamine (MDMA), 2,5-dimethoxy-4-methyl-phenethylamine (2C-D), 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B), 1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b'] difuran-4-yl)-2-aminoethane (2C-B-Fly), 4-ethylthio-2,5-dimethoxy-beta-phenethylamine (2C-T-2), 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I), and 4-ethyl-2,5-dimethoxy-beta-phenethylamine (2C-E), 1-(m-chlorophenyl)piperazine (m-CPP), 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DIPT) and 4-acetoxy-N,N-diisopropyltryptamine (4-acetoxy-DIPT) in urine of consumers using 3,4 methylendioxypropylamphetamine (MDPA) as internal standard. Sample preparation involved a solid-phase extraction procedure at pH 6 of both non-hydrolyzed and enzymatically hydrolyzed urine samples. Chromatography was performed on a C(18) reversed-phase column using a linear gradient of 10mM ammonium bicarbonate, pH 7.3 and acetonitrile as a mobile phase. Separated analytes were determined in LC-MS single ion monitoring mode using an atmospheric pressure ionization-electrospray ionization (ESI) interface. The assay was tested on urine samples from consumers of compounds under investigation (n=32). Limits of quantification varied between 20 and 60 ng/mL for the different analytes under investigation. Calibration curves were linear to 2000 ng/mL for all the substances under investigation, with a minimum r(2)>0.99. At three concentrations spanning the linear dynamic range of the assay, mean recoveries ranged between 55.4 and 95.6% for the different analytes. Higher analytes concentrations in hydrolyzed samples showed the presence of conjugated compounds in urine.